These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611 [TBL] [Abstract][Full Text] [Related]
46. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238 [TBL] [Abstract][Full Text] [Related]
47. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Ardiani A; Farsaci B; Rogers CJ; Protter A; Guo Z; King TH; Apelian D; Hodge JW Clin Cancer Res; 2013 Nov; 19(22):6205-18. PubMed ID: 24048332 [TBL] [Abstract][Full Text] [Related]
48. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial. Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795 [TBL] [Abstract][Full Text] [Related]
49. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904 [TBL] [Abstract][Full Text] [Related]
50. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538 [TBL] [Abstract][Full Text] [Related]
51. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. Rathkopf DE; Beer TM; Loriot Y; Higano CS; Armstrong AJ; Sternberg CN; de Bono JS; Tombal B; Parli T; Bhattacharya S; Phung D; Krivoshik A; Scher HI; Morris MJ JAMA Oncol; 2018 May; 4(5):694-701. PubMed ID: 29522174 [TBL] [Abstract][Full Text] [Related]
52. Abiraterone in metastatic prostate cancer without previous chemotherapy. Ryan CJ; Smith MR; de Bono JS; Molina A; Logothetis CJ; de Souza P; Fizazi K; Mainwaring P; Piulats JM; Ng S; Carles J; Mulders PF; Basch E; Small EJ; Saad F; Schrijvers D; Van Poppel H; Mukherjee SD; Suttmann H; Gerritsen WR; Flaig TW; George DJ; Yu EY; Efstathiou E; Pantuck A; Winquist E; Higano CS; Taplin ME; Park Y; Kheoh T; Griffin T; Scher HI; Rathkopf DE; N Engl J Med; 2013 Jan; 368(2):138-48. PubMed ID: 23228172 [TBL] [Abstract][Full Text] [Related]
53. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis. Gomez-Veiga F; Szmulewitz RZ; Holzbeierlein J; Azad AA; Iguchi T; Villers A; Alcaraz A; Alekseev B; Shore ND; Rosbrook B; Zohren F; Ma J; Haas GP; Stenzl A; Armstrong AJ Eur Urol Oncol; 2024 Aug; 7(4):860-869. PubMed ID: 38072761 [TBL] [Abstract][Full Text] [Related]
54. The evolving role of enzalutamide on the treatment of prostate cancer. Nadal R; Bellmunt J Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021 [TBL] [Abstract][Full Text] [Related]
56. U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Ning YM; Brave M; Maher VE; Zhang L; Tang S; Sridhara R; Kim G; Ibrahim A; Pazdur R Oncologist; 2015 Aug; 20(8):960-6. PubMed ID: 26070917 [TBL] [Abstract][Full Text] [Related]
57. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Stenzl A; Dunshee C; De Giorgi U; Alekseev B; Iguchi T; Szmulewitz RZ; Flaig TW; Tombal B; Morlock R; Ivanescu C; Ramaswamy K; Saad F; Armstrong AJ Eur Urol; 2020 Oct; 78(4):603-614. PubMed ID: 32336645 [TBL] [Abstract][Full Text] [Related]
58. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841 [TBL] [Abstract][Full Text] [Related]
59. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer. Bennett LL; Ingason A Ann Pharmacother; 2014 Apr; 48(4):530-7. PubMed ID: 24458946 [TBL] [Abstract][Full Text] [Related]
60. Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer. Keating GM Drugs Aging; 2015 Mar; 32(3):243-9. PubMed ID: 25711765 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]